Transgene-Tasly JV Reports Immunotherapy Progress

Transgene SA, a French immunotherapy company, reported that its 50-50 joint venture with Tianjin Tasly Pharma currently has three drug candidates in pre-clinical development. The two companies established the JV in 2010 with the goal of developing biologic drugs for the China market. Tasly is a TCM drug company. The JV’s lead product is TG1050, an adenovirus-based targeted immunotherapy aimed at treating chronic hepatitis B. More details.... Stock Symbols: (PA: TNG) (SHA: 600535) Share this with colleagues: // //